A series of androgen receptor modulators based on 8H- [1,4]oxazino[2,3-f]quinolin-8-ones was synthesized and evaluated in an androgen receptor transcriptional activation assay. The most potent analogues from the series exhibited single-digit nanomolar potency in vitro. Compound 18h demonstrated full efficacy in the maintenance of muscle weight, at 10 mg/kg, with reduced activity in prostate weight in an in vivo model of androgen action.The androgen receptor (AR) is a member of the intracellular receptor superfamily of liganddependent transcription factors. 1 The endogenous ligands for AR are the steroids testosterone (T) and dihydrotestosterone (DHT). When bound to AR, these ligands play important roles in sexual development and function, 2 and musculo-skeletal growth. 3 Steroidal androgen therapy is effective for the treatment of androgen insufficiency. However, the broader use of these androgens for additional treatments, such as osteoporosis or frailty, is limited by undesirable AR-mediated effects, such as prostatic hypertrophy and hirsutism. A selective androgen receptor modulator (SARM), with full anabolic activity but reduced impact on the undesirable effects could have a large role on endocrine therapies to treat muscle wasting and osteoporosis. 4 Early studies on modified androgens explored alkylation at C-17, as in fluoxymesterone (1 , Figure 1). 5 However, compounds from this general class are associated with potential liver toxicity. 2 Recent publications in the area of nonsteroidal androgens is indicative of the high level in discovering novel safe, effective anabolic agents (2, 3). [6][7][8] Our continued interest in SARMs is based on scaffolds derived from quinolin-2-ones (4 and 5). 9,10 During the course of our studies on 7H-[1,4]oxazino[3,2-g]quinolin-7-ones (5a), we isolated as a minor byproduct of the Knorr quinolone reaction 11 regioisomer (6a, <5% yield, Scheme 1) which fortuitously possessed AR agonist activity in a transcriptional activation assay (78% agonist efficacy, 5 nM). Investigations into the scaffold led to a series of novel androgens derived from 8H-[1,4]oxazino[2,3-f]quinolin-8-ones (6). The lead compound from this series, 18h, demonstrated full efficacy in the maintenance of levator ani weight (LA) muscle, an anabolic endpoint in a castrated mature rat model.Our previous investigations of quinolinone scaffolds 4 and 5 revealed that the regions proximal to the tertiary amine group strongly affected AR activity. Consequently, we sought to probe